Sirio Pharma Faces Market Sentiment Shift Amid Mixed Financial Performance and High Leverage

Sirio Pharma Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a shift in its technical score, indicating a change in market sentiment towards the stock. Key financial metrics reveal a mixed picture for Sirio Pharma. The company reported flat financial performance for the quarter ending September 2025, with an interest coverage ratio at its lowest point of 447.45. Additionally, cash and equivalents stood at CNY 1,195.3 million, marking a significant figure in its liquidity position. The debt-equity ratio has reached a high of 41.48%, suggesting a notable leverage level. Despite a return of -19.13% over the past year and a profit decline of -11.7%, the company maintains a high dividend yield of 1.7%. The return on equity (ROE) is recorded at 11.90%, but the valuation appears elevated with a price-to-book ratio of 2.88. Furthermore, Sirio Pharma has underperformed against the China Shanghai Composite index over various time frames, indicating challenges in its market position. For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.